AMRI promotes Richard A. Saffee to Vice President and General Manager of Large Scale Manufacturing

14-Jan-2013 - USA

AMRI announced that Richard A. Saffee has been promoted to the newly created role of Vice President and General Manager of Large Scale Manufacturing, effective immediately. He will continue to report to Steven R. Hagen, Ph.D., Senior Vice President of Pharmaceutical Development and Manufacturing.

Mr. Saffee will assume oversight for large scale manufacturing in Aurangabad, India in addition to his current responsibilities for leadership of AMRI's large scale manufacturing and GMP business in the United States in the Capital Region of New York. Additionally, Mr. Saffee will work with AMRI's Holywell, UK site to assist them in their large scale manufacturing business.

Before coming to AMRI, Mr. Saffee led manufacturing activities for multiple U.S.-based operations for Pfizer Global Manufacturing. and Pfizer Global Human Health.  Prior to the acquisition of Parke-Davis by Pfizer, Mr. Saffee held roles of increasing responsibility at Parke-Davis including Director of Chemical Manufacturing and Area Production Manager.

Mr. Saffee earned a Master's degree in Business Administration from Grand Valley State University in Allendale, Michigan and a Bachelor's of Science degree in Chemical Engineering from the University of Michigan in Ann Arbor, Michigan.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

AMRI Hires Director of In Vitro Biology in Singapore

Action Pharma reports positive results in a proof of concept phase IB study in obese human volunteers treated with AP1030

Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist - Company Anticipates Initiating Phase 2a Studies by Early 2012

Elbion AG appoints Dr. Thomas Taapken as Chief Financial Officer and Member of the Executive Board

Galapagos and CHDI Foundation, Inc. enter new five-year collaboration for Huntington's disease therapeutics

Glaxosmithkline and Elbion to Collaborate on Development and Commercialisation of a new DE IV Inhibitor

RIKEN: Discovery of DNA Silencing Mechanism Reveals How Plants Protect Their Genome

Novasep invests EUR 30 million to build world's largest chromatography plant for the pharmaceutical industry - New plant on its Mourenx, France site to produce a large volume commercial API

Prosensa Announces Progress on Exon Skipping Compounds for the Treatment of Duchenne Muscular Dystrophy - £10m in milestone payments received from GlaxoSmithKline

KINAXO Biotechnologies receives 1 million EUR funding to quantify drug interactions with cellular protein targets

Effectiveness of drug to improve natriuretic peptide levels for chronic heart failure

Dyax Corp. and Cubist Pharmaceuticals, Inc. Sign Development and Commercialization Agreement for DX-88 Surgical Indications